VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects.
about
A role for the podosome/invadopodia scaffold protein Tks5 in tumor growth in vivoMore sound cancer therapy biomarker development with active noise control.Microbubble and ultrasound radioenhancement of bladder cancer.Computational modelling of anti-angiogenic therapies based on multiparametric molecular imaging dataDiffusion MRI quality control and functional diffusion map results in ACRIN 6677/RTOG 0625: a multicenter, randomized, phase II trial of bevacizumab and chemotherapy in recurrent glioblastoma.Identifying mRNA targets of microRNA dysregulated in cancer: with application to clear cell Renal Cell Carcinoma.Noninvasive evaluation of antiangiogenic effect in a mouse tumor model by DCE-MRI with Gd-DTPA cystamine copolymers.Bevacizumab-induced tumor vessel remodeling in rhabdomyosarcoma xenografts increases the effectiveness of adjuvant ionizing radiation.Delta-like ligand 4: A predictor of poor prognosis in clear cell renal cell carcinomaWhich patients with renal cancer may benefit from sunitinib therapy?The effect of chemotherapeutic agents on tumor vasculature in subcutaneous and orthotopic human tumor xenografts.Production of Novel VHH Nanobody Inhibiting Angiogenesis by Targeting Binding Site of VEGF.Semaphorin 3A overcomes cancer hypoxia and metastatic dissemination induced by antiangiogenic treatment in miceAntiangiogenic therapy for glioma.A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515.The complex role of angiopoietin-2 in the angiopoietin-tie signaling pathway.Discovery of Novel Small Molecule Inhibitors of VEGF Expression in Tumor Cells Using a Cell-Based High Throughput Screening Platform.The Prognosis of Anti-Angiogenesis Treatments Combined with Standard Therapy for Newly Diagnosed Glioblastoma: A Meta-Analysis of Randomized Controlled TrialsSafety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas.Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader StudyTargeted nanomaterials for radiotherapy.VEGF and Delta-Notch: interacting signalling pathways in tumour angiogenesis.TRPV4 channels regulate tumor angiogenesis via modulation of Rho/Rho kinase pathwayDynamic MRI using iron oxide nanoparticles to assess early vascular effects of antiangiogenic versus corticosteroid treatment in a glioma model.Molecular Biomarkers of Response to Antiangiogenic Therapy for Cancer.Angiogenesis as a therapeutic target in malignant gliomas.Antiangiogenic strategies for treatment of malignant gliomas.Oxidative stress in angiogenesis and vascular diseasePazopanib: therapeutic developments.Cardiovascular and systemic microvascular effects of anti-vascular endothelial growth factor therapy for cancer.Tumor vasculature as target for therapeutic intervention.Angiogenesis-related molecular targets in esophageal cancer.Anti-angiogenic therapy in glioma.Canine mammary tumours, an overview.Systemic therapy for advanced renal cell carcinoma.Dll4-Notch signaling as a therapeutic target in tumor angiogenesis.Inflammation and oxidative stress in angiogenesis and vascular disease.Update on anti-angiogenic treatment for malignant gliomas.Current and investigational pharmacotherapeutic approaches for modulating retinal angiogenesis.The roles of microRNA-34b-5p in angiogenesis of thyroid carcinoma.
P2860
Q24322028-4CDD811C-B423-486A-A023-0EB1391EA921Q30442454-C679D51B-E593-4338-BE14-85AF7CB7EE49Q30451819-8EB50AE2-036E-4D13-8226-884277223C1AQ30564565-005E90D3-41F8-40AF-A59E-C8D2683899B7Q30891381-0532CFDF-D9D2-4C04-899C-D3405B9860EBQ33565049-3BB107E3-240F-46C3-9F8E-48513461C43CQ33625077-221288B5-A513-4869-9036-3CD09FE32B36Q33995820-06DE55C1-EE6F-44F2-B7D5-7A95FC436E80Q34427294-FB37891F-EF7B-49B4-92C4-86F7000D48CBQ35076248-9F1F3C7E-4A97-4927-8093-2C40B2891265Q35187507-3DAE2703-EB48-488A-A3E7-DE5CEC290C14Q35657061-938A5406-3157-4302-8D5C-960770479275Q35913662-02204737-BBC0-4D88-8570-4405676A0E26Q36101999-14FEFE59-EBEA-44CA-8DAD-82EE09949FAFQ36163040-DDAB2249-0E94-47D3-944B-40770FEE3931Q36186523-B9F40A61-6DD6-4F4D-81B2-B0F79C915567Q36228258-518ED591-B432-41DE-8DDB-413946CBBE5AQ36231572-84C678A1-AC06-4225-A793-3B3F80AAD8C3Q36860502-BC72E14A-F7A0-4E88-878E-DE04E3C93128Q36943907-7802D441-A6B7-4004-9FEF-807D761A703FQ37038825-BE70AD94-1B50-458B-A529-33842F38C4F5Q37283444-DA86BC39-ED4F-4F74-9799-C4E482F45554Q37295520-E1AA1039-01DB-4201-8295-099D21E5D212Q37354846-3F2838DE-30EB-4056-A581-96808DDE7F44Q37377316-266C94DE-7F76-405D-8F0A-AF82487086DCQ37504362-60C61F72-A712-40F6-B0E8-D1D3B31B6B2DQ37533652-9CACE626-452B-42A4-9608-899FD64EA133Q37535220-D6B179B7-3ED6-43DE-B599-D686F0EB504AQ37642770-A85946B3-68CB-403A-8273-968894F7DA6CQ37658505-A69F3EDE-B83B-49E2-8DE4-F90121B56F93Q37800110-E2D4CC1E-440E-4B56-9B11-BA40A02967EFQ37858534-20595B78-76F9-4BB3-8727-044D62B0ABEBQ37877409-B0393B97-68F2-4F7A-96A6-86DEA60CB454Q37885436-925CFF92-9A5D-47C1-AB19-6E09F617C48DQ37905583-4A51AAA0-7BAA-411C-BDC6-D216C1F5B207Q37933528-3D169D9B-BB08-4369-B1BE-354DCDE0F116Q38083584-63470089-9C81-4B35-9AC2-CD1C46A4A8C3Q38186658-4D3FB39E-DF5E-4706-82FE-739181DEDC96Q38192060-6240CF43-B767-40DE-8ECD-128E3E67002DQ38694209-CF341597-A8FE-4E29-AD21-390FFBE09DCC
P2860
VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects.
@ast
VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects.
@en
type
label
VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects.
@ast
VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects.
@en
prefLabel
VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects.
@ast
VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects.
@en
P2093
P2860
P1476
VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects.
@en
P2093
Christopher G Willett
Dan G Duda
Rakesh K Jain
Tracy T Batchelor
P2860
P304
P356
10.1016/J.MOLMED.2007.04.001
P577
2007-04-25T00:00:00Z